Effects of Fasudil on Patients with Pulmonary Hypertension Associated with Left Ventricular Heart Failure with Preserved Ejection Fraction: A Prospective Intervention Study

Table 2

Cardiac effect of fasudil treatment determined by echocardiography.

Variable	PPH (n = 23)			RPH (n = 35)
	Pretreatment	Posttreatment		Pretreatment	Posttreatment
LAD (mm)	46.50 ± 4.75	45.50 ± 4.51	0.987	47.00 ± 6.25	46.63 ± 5.50	0.379
LVEDD (mm)	45.10 ± 6.14	46.07 ± 8.12	0.697	47.14 ± 8.40	47.63 ± 7.73	0.497
LVESD (mm)	27.91 ± 3.16	28.21 ± 2.88	0.378	29.02 ± 3.64	29.91 ± 4.06	0.788
IVST	11.01 ± 1.56	10.98 ± 1.96	0.916	11.85 ± 2.03	11.35 ± 1.96	0.895
LVPW	10.82 ± 1.16	10.01 ± 0.96	0.816	11.01 ± 1.76	10.87 ± 1.86	0.941
E (cm/s)	49.97 ± 6.85	52.59 ± 8.37	0.062	50.35 ± 8.22	53.43 ± 9.22	0.059
A (cm/s)	62.03 ± 10.31	63.36 ± 9.37	0.096	64.5 ± 11.80	54.52 ± 12.65	0.016
E′ (cm/s)	2.89 ± 1.03	3.03 ± 1.11	0.074	2.98 ± 1.16	4.05 ± 1.02	0.071
E/A	0.80 ± 0.11	0.83 ± 0.14	0.069	0.78 ± 0.19	0.98 ± 0.12	0.011
E/E′	17.29 ± 2.21	17.36 ± 1.89	0.098	16.89 ± 1.11	13.19 ± 1.79	0.011
EF (%)	61.64 ± 10.31	64.83 ± 12.37	0.069	62.43 ± 11.80	64.24 ± 9.65	0.485
PASP (mmHg)	49.87 ± 8.50	49.48 ± 8.64	0.444	64.37 ± 13.82^†	63.51 ± 13.79	0.017

Data are presented as mean ± standard deviation; differences in change from baseline between groups were evaluated using Student’s t-test; LAD, left atrial systolic diameter; LVEDD, left ventricular end-diastolic diameter; LVESD, left ventricular end-systolic diameter; IVST, interventricular septal thickness; LVPW, left ventricular posterior wall thickness; E, early diastolic transmitral flow velocity; A, late diastolic transmitral flow velocity; E′, early diastolic mitral annular velocity; ^†the comparison of PASP between groups before treatment, ; the change from baseline, .